| Market Cap | 60.41M | P/E | - | EPS this Y | 61.20% | Ern Qtrly Grth | - |
| Income | -78.39M | Forward P/E | -1.93 | EPS next Y | -30.90% | 50D Avg Chg | -16.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -25.00% |
| Dividend | N/A | Price/Book | 1.21 | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 39.02 | Shares Outstanding | 19.99M | 52W Low Chg | 38.00% |
| Insider Own | 6.35% | ROA | -32.71% | Shares Float | 15.42M | Beta | 0.92 |
| Inst Own | 38.39% | ROE | -49.07% | Shares Shorted/Prior | 643.20K/392.19K | Price | 0.29 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 2,380,248 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 5,956,213 | Change | -8.52% |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.